Clinical Pharmacology of Elagolix: An Oral Gonadotropin-Releasing Hormone Receptor Antagonist for Endometriosis

Treatment of Endometriosis-Associated Pain with Elagolix, an Oral GnRH Antagonist

Taylor, H. S., Giudice, L. C., Lessey, B. A., Abrao, M. S., Kotarski, J., Archer, D. F., Diamond, M. P., Surrey, E., Johnson, N. P., Watts, N. B., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1700089 · Cited by 511 · see citing works

Fat and bone

Reid, I. R. (2010) · Archives of Biochemistry and Biophysics · doi:10.1016/j.abb.2010.06.027 · Cited by 368 · see citing works

Long-Term Outcomes of Elagolix in Women With Endometriosis: Results From Two Extension Studies

Surrey, E., Taylor, H. S., Giudice, L., Lessey, B. A., Abrao, M. S., Archer, D. F., Diamond, M. P., Johnson, N. P., Watts, N. B., Gallagher, J. C., et al. (2018) · Obstetrics & Gynecology · doi:10.1097/aog.0000000000002675 · Cited by 139 · see citing works

Reproductive Sciences in 2009

Taylor, H. S. (2009) · Reproductive Sciences · doi:10.1177/1933719108329094 · Cited by 133 · see citing works

Suppression of Gonadotropins and Estradiol in Premenopausal Women by Oral Administration of the Nonpeptide Gonadotropin-Releasing Hormone Antagonist Elagolix

Struthers, R. S., Nicholls, A. J., Grundy, J. S., Chen, T., Jimenez, R., Yen, S. S. C., & Bozigian, H. P. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2008-1695 · Cited by 127 · see citing works

Discovery of Sodium R-(+)-4-{2-[5-(2-Fluoro-3-methoxyphenyl)-3-(2-fluoro-6-[trifluoromethyl]benzyl)-4-methyl-2,6-dioxo-3,6-dihydro-2H-pyrimidin-1-yl]-1-phenylethylamino}butyrate (Elagolix), a Potent and Orally Available Nonpeptide Antagonist of the Human Gonadotropin-Releasing Hormone Receptor

Chen, C., Wu, D., Guo, Z., Xie, Q., Reinhart, G. J., Madan, A., Wen, J., Chen, T., Huang, C. Q., Mi, C., et al. (2008) · Journal of Medicinal Chemistry · doi:10.1021/jm8006454 · Cited by 120 · see citing works

The beneficial effects of body fat and adipose tissue in humans*

Norgan, N. G. (1997) · International Journal of Obesity · doi:10.1038/sj.ijo.0800473 · Cited by 113 · see citing works

Dose-dependent suppression of gonadotropins and ovarian hormones by elagolix in healthy premenopausal women

Ng, J., Chwalisz, K., Carter, D. C., & Klein, C. E. (2017) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2016-3845 · Cited by 110 · see citing works

Racial/ethnic differences in bone mineral density among older women

Nam, H., Kweon, S., Choi, J., Zmuda, J. M., Leung, P., Lui, L., Hill, D. D., Patrick, A. L., & Cauley, J. A. (2012) · Journal of Bone and Mineral Metabolism · doi:10.1007/s00774-012-0402-0 · Cited by 98 · see citing works

Elagolix for the management of heavy menstrual bleeding associated with uterine fibroids: results from a phase 2a proof-of-concept study

Archer, D. F., Stewart, E. A., Jain, R. I., Feldman, R., Lukes, A. S., North, J., Soliman, A. M., Gao, J., Ng, J., & Chwalisż, K. (2017) · Fertility and Sterility · doi:10.1016/j.fertnstert.2017.05.006 · Cited by 81 · see citing works

Elagolix Alone or With Add-Back Therapy in Women With Heavy Menstrual Bleeding and Uterine Leiomyomas

Carr, B. R., Stewart, E. A., Archer, D. F., Al-Hendy, A. A., Bradley, L., Watts, N. B., Diamond, M. P., Gao, J., Owens, C. D., Chwalisż, K., et al. (2018) · Obstetrics and Gynecology · doi:10.1097/aog.0000000000002933 · Cited by 72 · see citing works

Pharmacokinetic Effects of Isavuconazole Coadministration With the Cytochrome P450 Enzyme Substrates Bupropion, Repaglinide, Caffeine, Dextromethorphan, and Methadone in Healthy Subjects

Yamazaki, T., Desai, A. V., Goldwater, R., Han, D., Howieson, C., Akhtar, S., Kowalski, D. L., Lademacher, C., Pearlman, H., Rammelsberg, D., et al. (2016) · Clinical Pharmacology in Drug Development · doi:10.1002/cpdd.281 · Cited by 43 · see citing works

Brown adipose tissue and bone

Lidell, M. E., & Enerbäck, S. (2015) · International Journal of Obesity Supplements · doi:10.1038/ijosup.2015.7 · Cited by 32 · see citing works

The pharmacokinetics of sertraline in overdose and the effect of activated charcoal

Cooper, J. M., Duffull, S. B., Saiao, A., & Isbister, G. K. (2014) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.12500 · Cited by 30 · see citing works

Population Pharmacokinetics of Elagolix in Healthy Women and Women with Endometriosis

Winzenborg, I., Nader, A. M., Polepally, A. R., Liu, M., Degner, J. F., Klein, C. E., Mostafa, N. M., Noertersheuser, P. A., & Ng, J. (2018) · Clinical Pharmacokinetics · doi:10.1007/s40262-018-0629-6 · Cited by 27 · see citing works

Quantitative Assessment of Elagolix Enzyme-Transporter Interplay and Drug–Drug Interactions Using Physiologically Based Pharmacokinetic Modeling

Chiney, M. S., Ng, J., Gibbs, J. P., & Shebley, M. (2019) · Clinical Pharmacokinetics · doi:10.1007/s40262-019-00833-6 · Cited by 25 · see citing works

Racial/Ethnic Differences in Bone Mineral Density of Young Adults

Wilkin, L. D., Sims, T. D., Jackson, M., & Haddock, B. L. (2010) · International journal of exercise science · doi:10.70252/njio5473 · Cited by 20 · see citing works

Elagolix Pharmacokinetic Profiles in Women With Renal or Hepatic Impairment

Ng, J., Duan, W. R., Marbury, T. C., Schmidt, J. M., & Klein, C. E. (2018) · Clinical Pharmacology in Drug Development · doi:10.1002/cpdd.640 · Cited by 18 · see citing works

Elagolix: a promising oral GnRH antagonist for endometriosis-associated pain

Dun, E. C., & Taylor, H. S. (2017) · Oncotarget · doi:10.18632/oncotarget.22381 · Cited by 10 · see citing works

Elagolix improves quality of life in women with heavy menstrual bleeding associated with uterine fibroids: evidence from a phase 2B randomized trial

Diamond, M., Soliman, A. M., Gao, J., Owens, C., Chwalisż, K., & Archer, D. F. (2017) · Fertility and Sterility · doi:10.1016/j.fertnstert.2017.07.095 · Cited by 4 · see citing works

Endometriosis: Epidemiology, Classification, Pathogenesis, Treatment and Genetics (Review of Literature)

Smolarz, B., Szyłło, K., & Romanowicz, H. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms221910554 · Cited by 560 · see citing works

Targeting Oxidative Stress Involved in Endometriosis and Its Pain

Clower, L., Fleshman, T., Geldenhuys, W. J., & Santanam, N. (2022) · Biomolecules · doi:10.3390/biom12081055 · Cited by 145 · see citing works

Treatment of endometriosis-associated pain with linzagolix, an oral gonadotropin-releasing hormone–antagonist: a randomized clinical trial

Donnez, J., Taylor, H. S., Taylor, R. N., Akin, M. D., Tatarchuk, T. F., Wilk, K., Gotteland, J.-P., Lecomte, V., & Bestel, E. (2020) · Fertility and Sterility · doi:10.1016/j.fertnstert.2020.02.114 · Cited by 124 · see citing works

Ferroptosis and oxidative stress in endometriosis: A systematic review of the literature

Ni, C., & Li, D. (2024) · Medicine · doi:10.1097/md.0000000000037421 · Cited by 44 · see citing works

A Clinician's Guide to the Treatment of Endometriosis with Elagolix

Leyland, N. A., Estes, S. J., Lessey, B. A., Advincula, A. P., & Taylor, H. S. (2020) · Journal of Women s Health · doi:10.1089/jwh.2019.8096 · Cited by 41 · see citing works

Elagolix in the treatment of heavy menstrual bleeding associated with uterine fibroids in premenopausal women

Ali, M. K., Sara, A. R., & Hendy, A. A. (2021) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2021.1900726 · Cited by 30 · see citing works

Physiological and pharmacological overview of the gonadotropin releasing hormone

Casati, L., Ciceri, S., Maggi, R., & Bottai, D. (2023) · Biochemical Pharmacology · doi:10.1016/j.bcp.2023.115553 · Cited by 31 · see citing works

GnRH agonists and antagonists in therapy of symptomatic uterine fibroids – current roles and future perspectives

Ciebiera, M., Madueke-Laveaux, O. S., Feduniw, S., Ulin, M., Spaczyński, R., Zgliczyńska, M., Bączkowska, M., Zarychta, E., Łoziński, T., Ali, M. K., et al. (2023) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2023.2248890 · Cited by 29 · see citing works

Vitamins and Uterine Fibroids: Current Data on Pathophysiology and Possible Clinical Relevance

Ciebiera, M., Ali, M. K., Zgliczyńska, M., Skrzypczak, M., & Al-Hendy, A. A. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21155528 · Cited by 28 · see citing works

Ultra-sensitive and selective fluorescence approach for estimation of elagolix in real human plasma and content uniformity using boron-doped carbon quantum dots

Salman, B. I., Hassan, A. I., Hassan, Y. F., & Saraya, R. E. (2022) · BMC Chemistry · doi:10.1186/s13065-022-00849-3 · Cited by 26 · see citing works

Quantitative Assessment of Elagolix Enzyme-Transporter Interplay and Drug–Drug Interactions Using Physiologically Based Pharmacokinetic Modeling

Chiney, M. S., Ng, J., Gibbs, J. P., & Shebley, M. (2019) · Clinical Pharmacokinetics · doi:10.1007/s40262-019-00833-6 · Cited by 25 · see citing works

Discovery and Characterization of BAY 1214784, an Orally Available Spiroindoline Derivative Acting as a Potent and Selective Antagonist of the Human Gonadotropin-Releasing Hormone Receptor as Proven in a First-In-Human Study in Postmenopausal Women

Panknin, O., Wagenfeld, A., Bone, W., Bender, E., Nowak‐Reppel, K., Fernández‐Montalván, A. E., Nubbemeyer, R., Bäurle, S., Ring, S., Schmees, N., et al. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c01076 · Cited by 25 · see citing works

The Multifactorial Pathogenesis of Endometriosis: A Narrative Review Integrating Hormonal, Immune, and Microbiome Aspects

Datkhayeva, Z., Iskakova, A., Mireeva, A., Seitaliyeva, A., Skakova, R., Kulniyazova, G., Shayakhmetova, A., Koshkimbayeva, G., Sarmuldayeva, C., Nurseitova, L., et al. (2025) · Medicina · doi:10.3390/medicina61050811 · Cited by 28 · see citing works

Gonadotropin-Releasing Hormone Antagonists—A New Hope in Endometriosis Treatment?

Rzewuska, A., Żybowska, M., Sajkiewicz, I., Spiechowicz, I., Żak, K., Abramiuk, M., Kułak, K., & Tarkowski, R. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12031008 · Cited by 27 · see citing works

Assessment of Clinical Drug‐Drug Interactions of Elagolix, a Gonadotropin‐Releasing Hormone Receptor Antagonist

Polepally, A. R., Ng, J., Salem, A. H., Dufek, M. B., Parikh, A., Carter, D. C., Kamradt, K., Mostafa, N. M., & Shebley, M. (2020) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.1689 · Cited by 22 · see citing works

Exposure‐Safety Analyses Identify Predictors of Change in Bone Mineral Density and Support Elagolix Labeling for Endometriosis‐Associated Pain

Suleiman, A. A., Nader, A. M., Winzenborg, I., Beck, D., Polepally, A. R., Ng, J., Noertersheuser, P. A., & Mostafa, N. M. (2020) · CPT Pharmacometrics & Systems Pharmacology · doi:10.1002/psp4.12560 · Cited by 15 · see citing works

Drug–Drug Interaction Studies of Elagolix with Oral and Transdermal Low-Dose Hormonal Add-Back Therapy

Nader, A. M., Mostafa, N. M., Ali, F., & Shebley, M. (2020) · Clinical Pharmacokinetics · doi:10.1007/s40262-020-00921-y · Cited by 13 · see citing works

Gonadotropin-releasing hormone receptor inhibits triple-negative breast cancer proliferation and metastasis

Chen, C., & Lu, X. (2022) · Journal of International Medical Research · doi:10.1177/03000605221082895 · Cited by 13 · see citing works

A Review of GnRH Antagonists as Treatment for Abnormal Uterine Bleeding-Leiomyoma (AUB-L) and Their Influence on the Readiness of Service Members

Wright, D., Kim, J. W., Lindsay, H., & Catherino, W. H. (2022) · Military Medicine · doi:10.1093/milmed/usac078 · Cited by 11 · see citing works

Comparing the pharmacokinetic and pharmacodynamic qualities of current and future therapies for uterine fibroids

Evangelisti, G., Barra, F., Perrone, U., Donato, N. D., Bogliolo, S., Ceccaroni, M., & Ferrero, S. (2022) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2022.2113381 · Cited by 11 · see citing works

Discovery of the thieno[2,3-d]pyrimidine-2,4-dione derivative 21a: A potent and orally bioavailable gonadotropin-releasing hormone receptor antagonist

Zou, F., Wang, Y., Yu, D., Liu, C., Lu, J., Zhao, M., Ma, M., Wang, W., Jiang, W., Gao, Y., et al. (2022) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2022.114679 · Cited by 11 · see citing works

QSAR AND MOLECULAR DOCKING STUDY OF GONADOTROPIN-RELEASING HORMONE RECEPTOR INHIBITORS

Arthur, D. E., Soliman, M. E. S., Adeniji, S. E., Adedirin, O., & Peter, F. (2022) · Scientific African · doi:10.1016/j.sciaf.2022.e01291 · Cited by 10 · see citing works

Virtual Bioequivalence Assessment of Elagolix Formulations Using Physiologically Based Pharmacokinetic Modeling

Mukherjee, D., Chen, M., Shao, X., Ju, T.-C. R., Shebley, M., & Marroum, P. J. (2023) · The AAPS Journal · doi:10.1208/s12248-023-00794-6 · Cited by 10 · see citing works

Therapeutic effects of melatonin on endometriosis, targeting molecular pathways: Current knowledge and future perspective

Sharifi, M., Nikoo, N. R., Badehnoosh, B., Shafabakhsh, R., Asemi, R., Reiter, R. J., & Asemi, Z. (2023) · Pathology - Research and Practice · doi:10.1016/j.prp.2023.154368 · Cited by 8 · see citing works

The latest advances in the pharmacological management of endometriosis

Hartner, G., Husslein, H., Kuessel, L., Gstoettner, M., Tiringer, D., Wenzl, R. J., & Perricos, A. (2022) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2022.2045274 · Cited by 8 · see citing works

Interdisciplinary model‐informed drug development for extending duration of elagolix treatment in patients with uterine fibroids

Beck, D., Winzenborg, I., Gao, W., Mostafa, N. M., Chiuve, S. E., Owens, C. D., & Shebley, M. (2022) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.15440 · Cited by 7 · see citing works

Physiologically based pharmacokinetic modeling and simulations to inform dissolution specifications and clinical relevance of release rates on elagolix exposure

Mukherjee, D., Chiney, M. S., Shao, X., Ju, T.-C. R., Shebley, M., & Marroum, P. J. (2022) · Biopharmaceutics & Drug Disposition · doi:10.1002/bdd.2315 · Cited by 8 · see citing works

Breaking the silence: The role of extracellular vesicles in unraveling the diagnosis and treatment of endometriosis

Utkarsh, K., Srivastava, N., Papayannakos, C. J., Nayyar, A., Khan, A. U., & Haque, S. (2023) · Extracellular Vesicles and Circulating Nucleic Acids · doi:10.20517/evcna.2023.43 · Cited by 7 · see citing works

A Personalized Medicine Approach Using Clinical Utility Index and Exposure‐Response Modeling Informed by Patient Preferences Data

Winzenborg, I., Soliman, A. M., & Shebley, M. (2020) · CPT Pharmacometrics & Systems Pharmacology · doi:10.1002/psp4.12570 · Cited by 7 · see citing works

Opportunistic Challenges of Computer-aided Drug Discovery of Lipopeptides: New Insights for Large Molecule Therapeutics

Yadav, M. K., & Eswari, S. (2022) · Avicenna Journal of Medical Biotechnology · doi:10.18502/ajmb.v15i1.11419 · Cited by 7 · see citing works

Synthesis of [H‐3]‐ and [C‐14]‐labeled elagolix

Soli, E. D., Surber, B. W., & Reed, A. D. (2021) · Journal of Labelled Compounds and Radiopharmaceuticals · doi:10.1002/jlcr.3908 · Cited by 7 · see citing works

Population Pharmacokinetics of Elagolix in Combination with Low-Dose Estradiol/Norethindrone Acetate in Women with Uterine Fibroids

Beck, D., Winzenborg, I., Liu, M., Degner, J. F., Mostafa, N. M., Noertersheuser, P. A., & Shebley, M. (2021) · Clinical Pharmacokinetics · doi:10.1007/s40262-021-01096-w · Cited by 7 · see citing works

Contraception today and family planning: a comprehensive review and position statement on the ethical, medical, and social dimensions of modern contraception

Genazzani, A. R., Fidecicchi, T., Arduini, D., Benagiano, G., Birkhaeuser, M. H., Schenker, J. G., Strauss, J. F., Awad, D. V., Arnal, J., Bahamondes, L. G., et al. (2025) · Gynecological Endocrinology · doi:10.1080/09513590.2025.2543423 · Cited by 5 · see citing works

Validation of a quantitative systems pharmacology model of calcium homeostasis using elagolix Phase 3 clinical trial data in women with endometriosis

Stodtmann, S., Nader, A. M., Polepally, A. R., Suleiman, A. A., Winzenborg, I., Noertersheuser, P. A., Ng, J., Mostafa, N. M., & Shebley, M. (2021) · Clinical and Translational Science · doi:10.1111/cts.13040 · Cited by 5 · see citing works

Greenness assessment of micellar spectrofluorometric approach for determination of Elagolix: application to dosage form, content uniformity and human plasma

Ahmed, R. M. (2021) · Heliyon · doi:10.1016/j.heliyon.2021.e08521 · Cited by 5 · see citing works

Oriahnn: New Drug Approved for Treating Heavy Menstrual Bleeding in Women With Uterine Fibroids

Lynch, S. E., & Mayer, D. C. (2021) · Annals of Pharmacotherapy · doi:10.1177/10600280211015987 · Cited by 5 · see citing works

Pharmacokinetic considerations for gonadotropin-releasing hormone agonists and antagonists to treat endometriosis

Paoletti, A. M., Neri, M., Pilloni, M., Marotto, M. F., Giancane, E., Vallerino, V., Piras, B., Melis, G., Melis, V., Masciale, M. D. M., et al. (2025) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2025.2499550 · Cited by 4 · see citing works

New perspectives in managing chronic pelvic pain in endometriosis: the role of GnRH antagonists versus dienogest

Palumbo, M., Giampaolino, P., Pellicano, M., Graziano, V., Bifulco, G., & Corte, L. D. (2026) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2026.2657998 · Cited by 3 · see citing works

Inhibition of ovulation and pharmacologic mechanism of action of relugolix combination therapy

Duijkers, I. J. M., Klipping, C., Draeger, C., Schug, B. S., Wedemeyer, R., Li, Y., Ferreira, J. C. A., & Migoya, E. M. (2025) · Fertility and Sterility · doi:10.1016/j.fertnstert.2025.03.011 · Cited by 3 · see citing works

Effects of elagolix on the pharmacokinetics of omeprazole and its metabolites in healthy premenopausal women

Nader, A. M., Mostafa, N. M., Kim, E., & Shebley, M. (2022) · Clinical and Translational Science · doi:10.1111/cts.13247 · Cited by 2 · see citing works

Pharmacokinetic and Pharmacodynamic Profiles of Ethinylestradiol/Norgestimate Combination or Norethindrone upon Coadministration with Elagolix 150 mg Once Daily in Healthy Premenopausal Women

Feldman, R., Chiu, Y., Klein, C. E., & Ng, J. (2021) · Clinical Pharmacokinetics · doi:10.1007/s40262-021-00989-0 · Cited by 3 · see citing works

Elagolix Sodium: Novel GnRH Antagonist for the Treatment of Endometriosis

Bhatia, R. (2021) · doi:10.52916/jcar214007 · Cited by 3 · see citing works

Oral GnRH antagonists for ovulation suppression during ovarian stimulation protocols: systemic review and meta-analysis

Cohen, N., Zilbelicht, A., Nahshon, C., Seh, S., Lavie, O., & Oron, G. (2025) · Journal of Assisted Reproduction and Genetics · doi:10.1007/s10815-025-03496-4 · Cited by 2 · see citing works

Gynecological uses of GnRH antagonists: review article

Ruiz, D. E. C., Núñez, E. N. M., & Núñez-Troconis, J. (2022) · Obstetrics & Gynecology International Journal · doi:10.15406/ogij.2022.13.00654 · Cited by 3 · see citing works

Bioequivalence of Elagolix/Estradiol/Norethindrone Acetate Fixed‐Dose Combination Product: Phase 1 Results in Healthy Pre‐ and Postmenopausal Women

Chen, M., Marroum, P. J., Chiu, Y., Neenan, M., Mostafa, N. M., & Shebley, M. (2024) · Clinical Pharmacology in Drug Development · doi:10.1002/cpdd.1399 · Cited by 2 · see citing works

Development and Application of a Physiologically Based Pharmacokinetic Model for Elagolix in the Adult and Adolescent Population

Zhang, X., Wang, X., Li, R., Zhang, C., Du, J., Zhao, H., & Wen, Q. (2024) · Clinical Pharmacokinetics · doi:10.1007/s40262-024-01402-2 · Cited by 2 · see citing works

LC–MS-Compatible Chromatographic Method for Quantification of Potential Organic Impurities of Elagolix Sodium in Tablet Dosage Form with Identification of Major Degradation Products

Desai, P. R., Prajapati, R., & Chokshi, A. B. (2023) · Journal of AOAC International · doi:10.1093/jaoacint/qsad019 · Cited by 2 · see citing works

An Evidence-Based Review of Elagolix for the Treatment of Pain Secondary to Endometriosis

Urits, I., Adamian, L., Miro, P., Callan, J., Patel, P. M., Patel, M., Berger, A. A., Kassem, H., Kaye, A. D., & Viswanath, O. (2025) · Psychopharmacology Bulletin · doi:10.64719/pb.4390 · Cited by 4 · see citing works

Endometriosis in Adolescence

Shim, J. Y., & Laufer, M. R. (2022) · Springer eBooks · doi:10.1007/978-3-030-97236-3_12 · Cited by 1 · see citing works

Elagolix is porphyrogenic and may induce porphyric attacks in patients with the acute hepatic porphyrias

Ma, C. D., & Bonkovsky, H. L. (2022) · Molecular Genetics and Metabolism Reports · doi:10.1016/j.ymgmr.2022.100915 · Cited by 1 · see citing works

Neue Behandlungsoptionen mit GnRH-Antagonisten bei Endometriose und Uterus myomatosus

Küpker, W., Plathow, D., Bullerdiek, J., & Felberbaum, R. E. (2020) · Gynäkologische Endokrinologie · doi:10.1007/s10304-020-00329-8

Suplemento do IX Congresso SAMMG

(2021) · Revista Médica de Minas Gerais · doi:10.5935/2238-3182.v31supl.2

Pharmacogenomic Biomarkers

Seven, Z. G. T., Özen, D., & Özyazgan, S. (2022) · BENTHAM SCIENCE PUBLISHERS eBooks · doi:10.2174/9789815040463122010014

Potency of oral gonadotropin-releasing hormone antagonist as endometriosis-associated pain novel treatments: An updated meta-analysis of randomized controlled trials

Tjahyadi, D., Riyadi, A. S., Nugrahani, A. D., Ritonga, M. A., Rachmawati, A., & Madjid, T. H. (2025) · International Journal of Reproductive BioMedicine (IJRM) · doi:10.18502/ijrm.v23i9.20156 · Cited by 1 · see citing works

Generating Control Groups for Organ Impairment Studies: A Case‐Study Comparing Statistical and Population Pharmacokinetic‐Based Matching Approaches

Barry, J. M., Bhatnagar, S., Liu, W., & Mohamed, M. F. (2025) · CPT Pharmacometrics & Systems Pharmacology · doi:10.1002/psp4.70144

Pharmacokinetic–Pharmacodynamic Modeling and Simulation of Merigolix, a Nonpeptide Gonadotropin-Releasing Hormone Antagonist

Bae, S. H., Kang, J., Jeon, S., Kim, S. M., Kim, H.-T., Han, S., & Han, S. (2025) · Clinical Pharmacokinetics · doi:10.1007/s40262-025-01595-0

Additional file 1 of Ultra-sensitive and selective fluorescence approach for estimation of elagolix in real human plasma and content uniformity using boron-doped carbon quantum dots

Salman, B. I., Hassan, A. I., Hassan, Y. F., & Saraya, R. E. (2022) · Figshare · doi:10.6084/m9.figshare.20430635

Development, Optimization Using Box–Behnken, In Vitro, Ex Vivo Characterization & Pharmacokinetic Evaluation of Elagolix Sodium Loaded Self-Nano Emulsifying Drug Delivery SystemPreprint

Panwar, J., Garg, G., & Ali, H. (2026) · Research Square · doi:10.21203/rs.3.rs-8424074/v1

Efficacy and Tolerability of Elagolix in Adolescents and Young Adults with Endometriosis: A Small, Single-Center Retrospective Cohort Study

Shim, J. Y., Scatoni, A., Laufer, M. R., & Boskey, E. R. (2026) · Journal of Pediatric and Adolescent Gynecology · doi:10.1016/j.jpag.2026.02.008

Ovarian Escape in Hormone Receptor-Positive Breast Cancer: Mechanisms, Risk Factors, Clinical Consequences, and Management Strategies

Li, Y., & Wang, W. (2026) · Breast Cancer Targets and Therapy · doi:10.2147/bctt.s586408

Single‐Dose Bioequivalence Study of Elagolix Tablets 200 mg (Test Product) and Elagolix Tablets 200 mg (Reference Product) in Healthy Non‐Pregnant, Non‐Lactating Premenopausal Female Subjects Under Fasting Conditions

Kumar, S., Khuroo, A. H., Quadros, R. R., Dharmadhikari, S. K., Khandhedia, C., Puppalwar, G., & Mane, A. (2026) · Clinical Pharmacology in Drug Development · doi:10.1002/cpdd.70053

Expert opinion by Federation of Obstetric and Gynaecological Societies of India on elagolix − Redefining the endometriosis therapy landscape

Tandulwadkar, S. R., Mukherjee, B., Ganpule, C., Patel, M., Mallya, S., Gopinath, P., & Tiwari, B. (2026) · European Journal of Obstetrics & Gynecology and Reproductive Biology · doi:10.1016/j.ejogrb.2026.115115

Oral Gonadotropin-Releasing Hormone Antagonists for the Treatment of Endometriosis-Associated Pain: A Systematic Review and Meta-Analysis

Hsu, R. C., Han, E. S., Farrow, M., Pacis, M., Swartz, S., & Denny, K. (2026) · Journal of Minimally Invasive Gynecology · doi:10.1016/j.jmig.2026.04.004 · Cited by 1 · see citing works

Efficacy and Safety of Elagolix Versus Dienogest for Treatment of Moderate‐to‐Severe Endometriosis Pain: A Phase III , Multicentric, Double‐Blind, Active‐Controlled, Non‐Inferiority Study

Bhoir, S., Patel, J. N., Palve, T., Dash, M. K., Saigal, S., Kamilya, G., Srivastava, S., Savalia, K., Gupta, T., Choudhary, D., et al. (2026) · BJOG An International Journal of Obstetrics & Gynaecology · doi:10.1111/1471-0528.70256

GnRH antagonists for the treatment of fibroids and adenomyosis, current evidence and future perspectives

Ferrero, S., Gazzo, I., Perrone, U., Olcese, F., Ottonello, S., Rosato, F. P., Vellone, V. G., & Barra, F. (2026) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2026.2695094

BindingDB Entry 50019800: Discovery of the thieno[2,3-d]pyrimidine-2,4-dione derivative 21a: A potent and orally bioavailable gonadotropin-releasing hormone receptor antagonist.

BindingDB (2024) · UC San Diego · doi:10.7270/q2tx3ksv

BindingDB Entry 50011550: Discovery and Characterization of BAY 1214784, an Orally Available Spiroindoline Derivative Acting as a Potent and Selective Antagonist of the Human Gonadotropin-Releasing Hormone Receptor as Proven in a First-In-Human Study in Postmenopausal Women.

BindingDB (2022) · UC San Diego · doi:10.7270/q26d5xk9

Population Pharmacokinetics of Elagolix in Healthy Women and Women with Endometriosis

Winzenborg, I., Nader, A. M., Polepally, A. R., Liu, M., Degner, J. F., Klein, C. E., Mostafa, N. M., Noertersheuser, P. A., & Ng, J. (2018) · Clinical Pharmacokinetics · doi:10.1007/s40262-018-0629-6 · Cited by 27 · see citing works

Population Pharmacokinetics of Elagolix in Combination with Low-Dose Estradiol/Norethindrone Acetate in Women with Uterine Fibroids

Beck, D., Winzenborg, I., Liu, M., Degner, J. F., Mostafa, N. M., Noertersheuser, P. A., & Shebley, M. (2021) · Clinical Pharmacokinetics · doi:10.1007/s40262-021-01096-w · Cited by 7 · see citing works

Effect of Elagolix Exposure on Clinical Efficacy End Points in Phase III Trials in Women With Endometriosis‐Associated Pain: An Application of Markov Model

Winzenborg, I., Polepally, A. R., Nader, A. M., Mostafa, N. M., Noertersheuser, P. A., & Ng, J. (2020) · CPT Pharmacometrics & Systems Pharmacology · doi:10.1002/psp4.12545 · Cited by 3 · see citing works

Assessment of Clinical Drug‐Drug Interactions of Elagolix, a Gonadotropin‐Releasing Hormone Receptor Antagonist

Polepally, A. R., Ng, J., Salem, A. H., Dufek, M. B., Parikh, A., Carter, D. C., Kamradt, K., Mostafa, N. M., & Shebley, M. (2020) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.1689 · Cited by 22 · see citing works

Elagolix in endometriosis-related pain: a profile of its use as approved in the USA

Lyseng-Williamson, K. A. (2019) · Drugs & Therapy Perspectives · doi:10.1007/s40267-019-00606-y · Cited by 3 · see citing works